Graphene Photothermal Adjuvant Therapy for Mild Corona Virus Disease 2019: A Prospective Randomized Controlled Trial

Southeast University, China270 enrolled

Overview

This is a future-proof and randomized controlled clinical study on the clinical efficacy of graphene photothermal adjuvant therapy in Corona Virus Disease 2019(COVID-19) patients with mild symptoms. The objective is to examine the effect of graphene photothermal adjuvant therapy on the time line for such Corona Virus Disease 2019 patients to achieve a negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid test result, and their duration of disease. Patients who meet study criteria will be randomized into the Grapheme adjuvant therapy combined with conventional therapy group (treatment group) and the conventional therapy only group (control group). Contrasted to the control groups, the treatment groups will undergo 30-min of graphene adjuvant therapy every day for 7 d.

Following enrollment, patients will be randomized into treatment or control groups. All groups will receive the same conventional therapy. In addition, treatment groups will undergo Graphene adjuvant therapy 30 minutes per day for 7 d. Upon completion of the treatment protocol, specific study endpoints will be compared between the treatment and control groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

270

Conditions

COVID-19

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Meet the diagnostic criteria for mild COVID-19. * Patients aged 18-60 years (inclusive). * No later than 48 h after testing positive and the onset of clinical symptoms * Sign informed consent form. Exclusion Criteria: * Severe or critically patients with COVID-19. * Resting heart rate over 120 beats per minute. * Coronary heart disease patients with acute cardiac insufficiency. * Acute exacerbation of chronic obstructive pulmonary disease（COPD）. * Uncontrolled hypertension \[resting systolic blood pressure(SBP) more than 180 mmHg and diastolic blood pressure(DBP) more than 90 mmHg\]; uncontrolled diabetes(Random Plasma Glucose, RPG\>16.7mmol/L, HbA1C\>7.0%) * Patients with severe cardiovascular, hepatic, renal and hematopoietic diseases. * Pregnant or menstruating woman. * Known or suspected history of active tuberculosis or extrapulmonary tuberculosis, patients with brucellosis, pneumonia-related illness from other causes * COVID-19 patients for the second or more times * Those who cannot cooperate due to various reasons * Body temperature: more than 38℃.

Outcomes

Primary Outcomes

The time from positive at baseline to negative SARS-CoV-2 nucleic acid test

The time for grouped patients to receive a negative SARS-CoV-2 nucleic acid test result, including both ORF gene Ct value≥35 and N gene Ct value≥35.

Time frame: through study completion, an average of 10 days

Secondary Outcomes

Hospital stay

Time to hospitalization for COVID-19

Time frame: through study completion, an average of 15 days

Negative test rate within 7 days

the rate of negative test of patients

Time frame: 7 days

Mild to moderate rate within 14 days

Time frame: 14 days